Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abdulamir
 
NCT04753619
RCTniclosamidestandard of careCOVID 19 hospitalizedsome concern
75/75 inconclusive
    Ader (lopinavir/ritonavir plus interferon)
     
    NCT04315948
    RCTlopinavir/ritonavir plus interferon ß-1astandard of careCOVID 19 hospitalizedsome concern
    145/148 safety concern
    • statistically significant 30 % decrease in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 86 % increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 3.4-fold increase in arrhythmia with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 5.6-fold increase in elevated liver enzymes with a moderate degree of certainty due to some concern in risk of bias
    Ader (lopinavir/ritonavir)
     
    NCT04315948
    RCTlopinavir/ritonavirCOVID 19 hospitalizedsome concern
    -/- ongoing
      Alavi-moghaddam
       
      IRCT20200328046882N1
      RCTsofosbuvirCOVID 19 hospitalizedsome concern
      27/30 ongoing
        DisCoVeRy (remdesivir)
         
        NCT04315948
        RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
        429/428 no results
          Elgohary
           
          NCT04530422
          RCTsofosbuvir and ledipasvirCOVID 19 hospitalizedsome concern
          125/125 ongoing
            Gaitan-Duarte (Emtricitabine/Tenofovir)
             
            NCT04359095
            RCTtenofovir/emtricitabineCOVID 19 hospitalizedsome concern
            163/162 ongoing
              Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir)
               
              NCT04359095
              RCTEmtricitabine/tenofovir plus colchicine plus rosuvastatinstandard of careCOVID 19 hospitalizedsome concern
              163/162 suggested
              • inconclusive 38 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 30 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
              Mahajan RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
              41/41 inconclusive
                Mobarak S (DISCOVER)
                 
                IRCT20200624047908N
                RCTsofosbuvir and daclatasvirplaceboCOVID 19 hospitalizedsome concern
                541/542 inconclusive
                • inconclusive 3 % decrease in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
                Gonzalez (IVER)
                 
                NCT04391127
                RCTivermectinplaceboCOVID 19 hospitalizedsome concern
                36/37 inconclusive
                  Lou Y
                   
                  ChiCTR2000029544
                  RCTbaloxavir marboxilstandard of careCOVID 19 hospitalizedsome concern
                  10/10 inconclusive
                  • inconclusive 88 % decrease in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
                  NIH NIAID ACTT-1
                   
                  NCT04280705
                  RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
                  541/521 suggested
                  • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
                  • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
                  Nojomi
                   
                  IRCT20180725040596N2
                  RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
                  50/50 inconclusive
                    Nojomi
                     
                    IRCT20180725040596N2
                    RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
                    50/50 inconclusive
                      RECOVERY
                       
                      NCT04381936
                      RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
                      1616/3424 inconclusive
                      • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                      the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
                      RECOVERY (AZI, Horby)
                       
                      NCT04381936
                      RCTazithromycinstandard of careCOVID 19 hospitalizedsome concern
                      2582/5181 inconclusive
                      • inconclusive 3 % decrease in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Sadeghi
                       
                      IRCT20200128046294N2
                      RCTsofosbuvir and daclatasvirstandard of careCOVID 19 hospitalizedsome concern
                      35/35 suggested
                      • suggested 2.6-fold increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Sekhavati
                       
                      IRCT20200415047092N1
                      RCTazithromycinstandard of careCOVID 19 hospitalizedsome concern
                      56/55 inconclusive
                      • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                      SOLIDARITY (lopi/rito)
                       
                      NCT04315948
                      RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
                      1399/1372 inconclusive
                      • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                      SOLIDARITY (remdesivir)
                       
                      NCT04315948
                      RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
                      2750/2725 inconclusive
                      • inconclusive 5 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Yakoot
                       
                      DRKS00022203
                      RCTsofosbuvir and daclatasvirstandard of careCOVID 19 hospitalizedsome concern
                      44/45 suggested
                      • suggested 60 % increase in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias

                      COVID 19 all comers meta-analysis

                      Andreas (NOR-Solidarity)
                       
                      NCT04321616
                      RCTremdesivirCOVID 19 all comerslow
                      43/58 ongoing
                        Norwegian NOR study (remdesivir)
                         
                        NCT04321616
                        RCTremdesivirstandard of careCOVID 19 all comerssome concern
                        43/58 no results
                          Chang Chen et al.
                           
                          ChiCTR2000030254
                          RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
                          120/120 inconclusive
                          • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                          ELACOI (Standard of care)
                           
                          NCT04252885
                          RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
                          16/7 inconclusive
                            Lou (FAVIPIRAVIR)
                             
                            ChiCTR2000029544
                            RCTfavipiravir standard of careCOVID 19 all comerssome concern
                            10/10 inconclusive
                            • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
                            NCT04310228-FAVI (Zhao)
                             
                            ChiCTR2000030894
                            RCTfavipiravir tocilizumab COVID 19 all comerssome concern
                            -/- inconclusive
                            • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

                            COVID-19 mild to moderate meta-analysis

                            I-TECH (Lim)
                             
                            NCT04920942
                            RCTivermectincontrolCOVID-19 mild to moderatesome concern
                            241/249 inconclusive
                            • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                            FACCT Trial
                             
                            NCT04392973
                            RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
                            125/129 inconclusive
                            • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                            Kirti
                             
                            CTRI/2020/08/027225
                            RCTivermectinplaceboCOVID-19 mild to moderatesome concern
                            57/58 inconclusive
                            • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
                            Rashad A (AZI vs SoC) RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
                            107/99 inconclusive
                              Shinkai
                               
                              JapicCTI-205238
                              RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
                              107/49 safety concern
                              • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                              • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                              Solaymani-Dodaran
                               
                              IRCT20200318046812N1
                              RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
                              193/187 inconclusive
                                AVIFAVIR
                                 
                                NCT04434248
                                RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
                                20/20 suggested
                                • suggested 2.9-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
                                Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.
                                Chaccour
                                 
                                NCT04390022
                                RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
                                12/12 inconclusive
                                • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
                                COALITION I Covid-19 Brazil (AZI, Cavalcanti)
                                 
                                NCT04322123
                                RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
                                172/159 inconclusive
                                • inconclusive 18 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                Dabbous HM
                                 
                                NCT04349241
                                RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
                                50/50 inconclusive
                                  ELACOI (lopinavir/ritonavir)
                                   
                                  NCT04252885
                                  RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
                                  21/7 inconclusive
                                    ELACOI (Lopinavir/ritonavir)
                                     
                                    NCT04252885
                                    RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
                                    35/34 inconclusive
                                    • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
                                    • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
                                    GS-US-540-5773 (Goldman)
                                     
                                    NCT04292899
                                    RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
                                    200/197 suggested
                                    • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
                                    GS-US-540-5774, 10 days
                                     
                                    NCT04292730
                                    RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
                                    197/200 safety concern
                                    • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
                                    • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
                                    • statistically significant 63 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                                    The primary endpoint was not met, no odds ratio is reported because the proportional odds assumption was not met
                                    GS-US-540-5774, 5 days
                                     
                                    NCT04292730
                                    RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
                                    199/200 conclusif
                                    • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                                    Hung et al.
                                     
                                    NCT04276688
                                    RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
                                    86/41 conclusif
                                    • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                    • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
                                    Khamis RCTfavipiravir plus interferonstandard of careCOVID-19 mild to moderatesome concern
                                    44/45 inconclusive
                                      Krolewiecki
                                       
                                      NCT004381884
                                      RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
                                      30/15 inconclusive
                                        Li T
                                         
                                        NCT04273763
                                        RCTbromhexinestandard of careCOVID-19 mild to moderatesome concern
                                        12/6 suggested
                                        • inconclusive 52 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                                        • suggested 9.0-fold increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
                                        NCT04542694
                                         
                                        NCT04542694
                                        RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
                                        100/100 suggested
                                        • suggested 1.1-fold increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                        • suggested 12.0-fold increase in viral clearance with a moderate degree of certainty due to some concern in risk of bias
                                        Ren
                                         
                                        ChiCTR2000029853
                                        RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
                                        10/10 suggested
                                        • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
                                        Ruzhentsova T
                                         
                                        NCT04501783
                                        RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
                                        112/56 suggested
                                        • suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                        • inconclusive 28 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                        • suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
                                        • suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
                                        Shahbaznejad
                                         
                                        IRCT20111224008507N3
                                        RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
                                        35/38 inconclusive
                                          Udwadia
                                           
                                          CTRI/2020/05/025114
                                          RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
                                          75/75 safety concern
                                          • inconclusive 37 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                          • suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
                                          • suggested 94 % decrease in mechanical ventilation (time to event analysis only),mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
                                          • statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias

                                          COVID-19 severe or critically meta-analysis

                                          Galan
                                           
                                          RBR-8h7q82
                                          RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
                                          53/115 suggested
                                          • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                          • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
                                          Galan
                                           
                                          RBR-8h7q82
                                          RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
                                          53/115 suggested
                                          • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                          • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
                                          Cao
                                           
                                          ChiCTR2000029308
                                          RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
                                          99/100 suggested
                                          • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                          • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
                                          CAP-China (Wang et al.)
                                           
                                          NCT04257656
                                          RCTremdesivirplaceboCOVID-19 severe or criticallylow
                                          158/79 inconclusive
                                          • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
                                          COALITION II Covid-19 Brazil (Furtado)
                                           
                                          NCT04321278
                                          RCTazithromycinstandard of careCOVID-19 severe or criticallysome concern
                                          214/183 safety concern
                                          • inconclusive 26 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                                          • statistically significant 6 % decrease in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
                                          REMAP-CAP (lopinavir/ritonavir only)
                                           
                                          NCT02735707
                                          RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
                                          268/377 safety concern
                                          • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
                                          REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine)
                                           
                                          NCT02735707
                                          RCTLopinavir/ritonavir plus hydroxychloroquinestandard of careCOVID-19 severe or criticallysome concern
                                          29/377 safety concern
                                          • suggested 42 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
                                          • statistically significant 37 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
                                          44 studies excluded by filtering options (21 RCT / 23 OBS)

                                          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).